Sutro Biopharma (NASDAQ:STRO - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Sutro Biopharma to post earnings of ($0.63) per share and revenue of $11.61 million for the quarter.
Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.28). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The firm had revenue of $17.40 million for the quarter, compared to the consensus estimate of $11.61 million. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Sutro Biopharma Stock Performance
Sutro Biopharma stock traded down $0.09 during trading hours on Friday, reaching $0.87. 1,050,324 shares of the company's stock traded hands, compared to its average volume of 1,093,989. Sutro Biopharma has a fifty-two week low of $0.52 and a fifty-two week high of $5.17. The firm has a market capitalization of $73.46 million, a price-to-earnings ratio of -0.54 and a beta of 1.77. The firm's 50 day moving average is $0.85 and its 200-day moving average is $1.85.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on STRO. Citizens Jmp cut Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research note on Friday, March 14th. HC Wainwright reaffirmed a "neutral" rating and set a $2.00 price target on shares of Sutro Biopharma in a research report on Tuesday, April 29th. Piper Sandler set a $2.00 price objective on Sutro Biopharma in a research report on Friday, March 14th. Bank of America downgraded shares of Sutro Biopharma from a "buy" rating to an "underperform" rating and dropped their target price for the stock from $11.00 to $1.00 in a report on Friday, March 14th. Finally, Wedbush cut shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $8.00 to $2.00 in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, Sutro Biopharma has an average rating of "Hold" and an average price target of $6.63.
View Our Latest Report on Sutro Biopharma
About Sutro Biopharma
(
Get Free Report)
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Featured Articles

Before you consider Sutro Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.
While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.